Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions

Eli Lilly and CompanyJohn C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company (NYSE: LLY), urged that biopharmaceuticals be included in transatlantic trade and economic discussions. Lechleiter participated in the American Council on Germany's conference on "The Transatlantic Partnership in the 21st Century," joining U.S. Fed Chairman Paul Volcker; German State Secretary in the Federal Finance Ministry Jorg Asmussen; and Handlesblatt editor-in-chief Gabor Steingart in a panel discussion.

"Biopharmaceutical innovation has enormous global economic and social benefits," said Lechleiter. "New medicines are one of the most cost-effective investments we can make to improve health care and enable more efficient use of health care budgets. The whole world has a stake in policies in Europe and America that promote innovation and trade to address the vast unmet medical needs of growing and aging populations."

Even with these benefits, biopharmaceutical innovation is very susceptible to the political environment - both nationally and internationally. Lechleiter explained that responses to short-term cost pressures by government payers are hampering the sector, citing recent reforms in Germany as an example.

"We must ensure that health care reform in our countries will help promote biopharmaceutical innovation and not undermine it," said Lechleiter. "Health care reform should focus on creating value through the system - and that means promoting innovation and efficiency. Even the absolute requirements of our sector in global markets - intellectual property protection, supply chain security and anti-counterfeiting measures are far from secure."

To spur trans-Atlantic trade in pharmaceuticals and maintain medical innovation, Lechleiter called for:

  • consistent regulatory policies
  • intellectual property protection, and
  • harmonized systems to deal with common issues such as counterfeiting.

He noted a positive step is the recent Falsified Medicines Directive of the EU, which aims to create a comprehensive anti-counterfeiting system across the full length of the supply chain in Europe.

Lechleiter said the Transatlantic Economic Council (TEC) is a very positive step forward and pressed for inclusion of biotech/biopharmaceutical industries in the ongoing TEC discussions and meetings. The TEC was initially proposed by Chancellor Angela Merkel in 2007 to strengthen transatlantic economic cooperation between the U.S. and the EU.

"The TEC is an additional important forum which we should use to foster the growth of biotechnologies and promote biopharmaceutical innovation," said Lechleiter. "An increased focus on biotech and innovative pharmaceuticals would complement the TEC's existing efforts to advance the transatlantic harmonization of regulatory regimes affecting key future growth industries."

"Other industries - such as auto and green energy - are already working closely with the U.S. and European governments to advance discussions through the TEC," concluded Lechleiter. "Transatlantic cooperation in biopharma would not only lead to technological advancement and job growth on both sides of the Atlantic, but also benefit society through faster/broader access to life-saving medical therapies."

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...

Experimental COVID-19 vaccine protects upper and l…

Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper an...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...